“Grindeks” will participate in the international exhibition “CPhI Worldwide 2012” in Madrid

9/17/2012 7:17 AM EST

Grindeks
Company Announcement

“Grindeks” will participate in the international exhibition “CPhI Worldwide
2012” in Madrid

From 9 to 11 October, 2012, “Grindeks” will participate in the leading
pharmaceutical exhibition “CPhI Worldwide 2012” in Madrid, Spain. During the
exhibition “Grindeks” will meet with its existing business partners, as well as
introduce potential cooperation partners to its world class products and
services. “Grindeks” exhibition stand will be placed in the Hall 9 with number
9B58. 

Grindeks will promote cooperation in the following business fields:

  -- Complicated, multi-stage synthesis of APIs;
  -- FDF development and manufacturing of tablets, capsules, injections and
     topical forms;
  -- Customized contract manufacturing of FDF.

Another significant type of “Grindeks” cooperation with other pharmaceutical
companies is raw material purchases for manufacturing purposes. Therefore,
during the exhibition „CPhI Worldwide 2012” the company has an opportunity of
meeting the leading respective cooperation offerers, estimating and
investigating potential business partners. “Grindeks” goal is finding the most
economically advantageous tender for the raw material purchases. 

Chairman of the Board of JSC “Grindeks” Juris Bundulis admits: “This is an
important annual pharmaceutical event; therefore, taking into account the
successful experience in previous years, we will participate at the exhibition
for the fifth year in a row. At the exhibition we will meet our existing
clients, as well as seek for new, perspective cooperation opportunities.
Certainly, participation at the exhibition is an acknowledgement for our
competitiveness with other pharmaceutical companies. “Grindeks” is a
development-oriented company that has many advantages to compete successfully
in the global pharmaceutical market.  Our reputation, solutions and products
are appreciated by our cooperation partners, health-care specialists and
patients.” 

“CPhI Worldwide” is the world's most important pharmaceutical event, which, in
2012, is held for the 23rd time and gathers pharmaceutical product
manufacturers and related industry representatives from all over the world. 

The participation of “Grindeks” in “CPhI Worldwide 2012” is co-financed by the
European Regional Development Fund. 



About “Grindeks”

“Grindeks” is the leading pharmaceutical company in the Baltic States. Its main
fields of action are: research, development, manufacturing and sale of original
products, generics and active pharmaceutical ingredients. The Group of
“Grindeks” consists of four subsidiary companies in Latvia, Estonia and Russia,
as well representative offices in eleven countries. 

“Grindeks” specializes in the heart and cardiovascular, CNS and anti-cancer
medication therapeutic groups. A range of products covers a successful
combination of original products and generics, with the original products
Mildronate® and Ftorafur® and more than 100 forms of effective and safe
generics included therein. Currently “Grindeks” produces 22 active
pharmaceutical ingredients. 

Products of the company are exported to 50 countries and its export comprises
more than 95% of the total turnover. The main markets are: Russia and other CIS
countries, the Baltic States, Germany, the Netherlands, Japan and the U.S. In
2010 the Ministry of Economics of Republic of Latvia and the Investment and
Development Agency of Latvia awarded “Grindeks” as the most export potential
company of Latvia. 

During the last years the company realized many considerable investment
projects in purpose to increase production capacity and develop infrastructure
and invested 32.7 million lats within five years. 

JSC “Grindeks” shares are listed on the Official List of “NASDAQ OMX Riga”.
Major shareholders of JSC “Grindeks” are Kirovs Lipmans – 33.29%, Anna Lipmane
– 16.69%, “AB.LV Private Equity fund 2010” – 11.38%, “Skandinaviska Enskilda
Banken” (nominal holder) – 10.53%, “Swedbank” AS Clients Account (nominal
holder) – 8.79%. 

More information about the company – www.grindeks.lv/en/

Follow “Grindeks”: Twitter.com/AS_Grindeks; Youtube.com/GrindeksLV




         Further information:
         
         Laila Klavina
         
         Head of the Communications Department, JSC “Grindeks”
         
         Phones: (+371) 67083370, (+371) 29256012
         
         Fax: (+371) 67083505
         
         E-mail: